Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism

• Main Authors: Elizabeth Nunn (Author), Natasha Jaiswal (Author), Matthew Gavin (Author), Kahealani Uehara (Author), Megan Stefkovich (Author), Karima Drareni (Author), Ryan Calhoun (Author), Michelle Lee (Author), Corey D. Holman (Author), Joseph A. Baur (Author), Patrick Seale (Author), Paul M. Titchenell (Author)
• Format: Book
• Published: Elsevier, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Glucagon-like peptide 1 (GLP-1) receptor agonists reduce food intake, producing remarkable weight loss in overweight and obese individuals. While much of this weight loss is fat mass, there is also a loss of lean mass, similar to other approaches that induce calorie deficit. Targeting sig...